• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝硬化患者中艰难梭菌感染的危险因素。

Risk factors for Clostridium difficile infection in cirrhotic patients.

机构信息

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.

Department of Laboratory Medicine, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.

出版信息

Hepatobiliary Pancreat Dis Int. 2019 Jun;18(3):237-241. doi: 10.1016/j.hbpd.2019.04.003. Epub 2019 Apr 16.

DOI:10.1016/j.hbpd.2019.04.003
PMID:31029554
Abstract

BACKGROUND

Cirrhotic patients are susceptible to Clostridium difficile infection (CDI), however, the high risk factors are not clear. The present study aimed to identify the risk factors in cirrhotic patients with CDI.

METHODS

A total of 526 cirrhotic patients admitted to our hospital between May 2015 and October 2015 were included in this study. Stool samples were collected upon admission for the detection of CDI and toxin. CDI was monitored during the hospital stay. In total, 34 cases showed CDI. Then we analyzed the effects of age, sex, C. difficile colonization (CDC), multiple hospitalization, extended hospital stay, elevation of total bilirubin (TBIL), creatinine (Cr), Child-Pugh grade C, hepatic encephalopathy, hepatorenal syndrome, upper gastrointestinal hemorrhage, and exposure of antibiotics and proton pump inhibitor (PPI) on the CDI in cirrhotic patients.

RESULTS

Patients in the CDI group had more frequent CDC, multiple hospitalization, and extended hospital stay compared to those in the non-C. difficile infection (NCDI) group. Patients in the CDI group had higher TBIL and Cr, and higher frequency of Child-Pugh grade C, hepatic encephalopathy, upper gastrointestinal hemorrhage compared with those in the NCDI group. Multiple logistic regression analysis indicated that age >60 years (OR=1.689; 95% CI: 1.135-3.128), multiple hospitalization (OR=3.346; 95% CI: 1.392-8.043), length of hospital stay >20 days (OR=1.564; 95% CI: 1.113-2.563), hypoproteinemia (OR=4.962; 95% CI: 2.053-11.996), CDC (OR=18.410; 95% CI: 6.898-49.136), hepatic encephalopathy (OR=1.357; 95% CI: 1.154-2.368), and exposure of antibiotics (OR=1.865; 95% CI: 1.213-2.863) and PPI (OR=3.125; 95% CI: 1.818-7.548) were risk factors of CDI.

CONCLUSIONS

Age >60 years, multiple hospitalization, length of hospital stay >20 days, hypoproteinemia, CDC, hepatic encephalopathy, and exposure of antibiotics and PPI were risk factors for CDI in cirrhotic patients. These may contribute to the early diagnosis and monitoring of CDI in clinical practice.

摘要

背景

肝硬化患者易感染艰难梭菌(CDI),但高危因素尚不清楚。本研究旨在确定 CDI 肝硬化患者的危险因素。

方法

2015 年 5 月至 2015 年 10 月期间我院收治的 526 例肝硬化患者纳入本研究。入院时采集粪便样本进行 CDI 和毒素检测。住院期间监测 CDI。共 34 例出现 CDI。然后我们分析了年龄、性别、艰难梭菌定植(CDC)、多次住院、住院时间延长、总胆红素(TBIL)、肌酐(Cr)升高、Child-Pugh 分级 C、肝性脑病、肝肾综合征、上消化道出血以及暴露于抗生素和质子泵抑制剂(PPI)对肝硬化患者 CDI 的影响。

结果

CDI 组患者 CDC 发生率、多次住院和住院时间延长的频率高于非艰难梭菌感染(NCDI)组。与 NCDI 组相比,CDI 组患者的 TBIL 和 Cr 更高,Child-Pugh 分级 C、肝性脑病、上消化道出血的发生率更高。多因素 logistic 回归分析表明,年龄>60 岁(OR=1.689;95%CI:1.135-3.128)、多次住院(OR=3.346;95%CI:1.392-8.043)、住院时间>20 天(OR=1.564;95%CI:1.113-2.563)、低蛋白血症(OR=4.962;95%CI:2.053-11.996)、CDC(OR=18.410;95%CI:6.898-49.136)、肝性脑病(OR=1.357;95%CI:1.154-2.368)和暴露于抗生素(OR=1.865;95%CI:1.213-2.863)和 PPI(OR=3.125;95%CI:1.818-7.548)是 CDI 的危险因素。

结论

年龄>60 岁、多次住院、住院时间>20 天、低蛋白血症、CDC、肝性脑病以及暴露于抗生素和 PPI 是肝硬化患者 CDI 的危险因素。这些可能有助于临床实践中 CDI 的早期诊断和监测。

相似文献

1
Risk factors for Clostridium difficile infection in cirrhotic patients.肝硬化患者中艰难梭菌感染的危险因素。
Hepatobiliary Pancreat Dis Int. 2019 Jun;18(3):237-241. doi: 10.1016/j.hbpd.2019.04.003. Epub 2019 Apr 16.
2
Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe.2010年至2013年间艰难梭菌感染的负担:来自东欧一个学术中心的趋势和结果。
World J Gastroenterol. 2015 Jun 7;21(21):6728-35. doi: 10.3748/wjg.v21.i21.6728.
3
Clostridium difficile colonization and infection in patients with hepatic cirrhosis.肝硬化患者艰难梭菌定植与感染
J Med Microbiol. 2017 Oct;66(10):1483-1488. doi: 10.1099/jmm.0.000596. Epub 2017 Sep 25.
4
Proton Pump Inhibitors and the Risk for Hospital-Acquired Clostridium difficile Infection.质子泵抑制剂与医院获得性艰难梭菌感染的风险。
Mayo Clin Proc. 2013 Oct;88(10):1085-90. doi: 10.1016/j.mayocp.2013.07.004. Epub 2013 Sep 5.
5
Clostridium difficile Infection in Hospitalized Cirrhotic Patients with Hepatic Encephalopathy.肝硬化合并肝性脑病住院患者中艰难梭菌感染。
J Gastrointestin Liver Dis. 2015 Dec;24(4):423-8. doi: 10.15403/jgld.2014.1121.244.csd.
6
The evaluation of Clostridium difficile infection (CDI) in a community hospital.社区医院艰难梭菌感染(CDI)的评估。
J Infect Public Health. 2015 Mar-Apr;8(2):155-60. doi: 10.1016/j.jiph.2014.08.002. Epub 2014 Oct 6.
7
Incidence of Clostridium difficile infection in patients receiving high-risk antibiotics with or without a proton pump inhibitor.接受高风险抗生素治疗的患者中,使用质子泵抑制剂与不使用质子泵抑制剂的艰难梭菌感染发生率。
J Hosp Infect. 2016 Feb;92(2):173-7. doi: 10.1016/j.jhin.2015.10.009. Epub 2015 Nov 2.
8
Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure.质子泵抑制剂使用与抗生素暴露水平相关的艰难梭菌感染的差异风险。
Pharmacoepidemiol Drug Saf. 2011 Oct;20(10):1035-42. doi: 10.1002/pds.2198. Epub 2011 Aug 10.
9
Asymptomatic and yet C. difficile-toxin positive? Prevalence and risk factors of carriers of toxigenic Clostridium difficile among geriatric in-patients.无症状但艰难梭菌毒素呈阳性?老年住院患者中产毒艰难梭菌携带者的患病率及危险因素
BMC Geriatr. 2016 Nov 15;16(1):185. doi: 10.1186/s12877-016-0358-3.
10
Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection.连续质子泵抑制剂治疗与复发性艰难梭菌感染的相关风险。
JAMA Intern Med. 2015 May;175(5):784-91. doi: 10.1001/jamainternmed.2015.42.

引用本文的文献

1
Infection in Liver Cirrhosis: A Concise Review.肝硬化感染:简要综述。
Can J Gastroenterol Hepatol. 2022 Jun 7;2022:4209442. doi: 10.1155/2022/4209442. eCollection 2022.
2
Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial.质子泵抑制剂治疗肝硬化患者的停药研究(STOPPIT):一项前瞻性、多中心、对照、随机、双盲试验的研究方案。
Trials. 2022 Apr 12;23(1):302. doi: 10.1186/s13063-022-06232-w.
3
The Risk of Infection in Cirrhotic Patients Receiving Norfloxacin for Secondary Prophylaxis of Spontaneous Bacterial Peritonitis-A Real Life Cohort.
肝硬化患者接受诺氟沙星预防自发性细菌性腹膜炎的继发感染风险:一项真实世界队列研究。
Medicina (Kaunas). 2021 Sep 13;57(9):964. doi: 10.3390/medicina57090964.
4
infection in liver cirrhosis patients: A population-based study in United States.肝硬化患者的感染:一项基于美国人群的研究。
World J Hepatol. 2021 Aug 27;13(8):926-938. doi: 10.4254/wjh.v13.i8.926.
5
Treatment of infection.治疗感染。
Ann Med. 2020 Feb-Mar;52(1-2):12-20. doi: 10.1080/07853890.2019.1701703. Epub 2019 Dec 13.